PI3Kα controls tumour cell aggregation
INTRODUCTION
Ovarian cancer is ranked in the world 8th in cancer incidence, but 4th in female mortality (1) . It is often associated with a poor prognosis due to the frequent intraperitoneal implantation of tumour cells called peritoneal carcinomatosis observed at advanced stages (2, 3) . Found in about 89% of patients with a stade III or IV ovarian cancer, massive production of ascites fluid (inflammatory exudate present in peritoneal cavity) is in most cases associated with peritoneal carcinomatosis (4) (5) (6) . Unlike most solid cancers, ovarian cancer cells rarely migrate haematogeneously but has the particularity to disseminate by direct extension to neighboring organs especially via the transcoelomic pathway. By this mechanism, cancer cells detach from the primary tumor and are then passively transported by the fluid throughout the peritoneal cavity in proximity of its entire wall composed of peritoneum and omentum, hence allowing the development of peritoneal carcinomatosis at multiple foci (2, 3, 7, 8) . Several cellular and molecular events are necessary before the establishment of peritoneal tumour implants resulting from transcoelomic migration of ovarian tumour cells: i) resistance to anoïkis, ii) transcoelomic dissemination facilitated by the flow of the peritoneal fluid , iii) escape of tumour cells to immune surveillance, iv) formation of spheroids or tumourospheres from aggregation of tumour cells in the ascites fluid, v) production of ascitic fluid as a vector of dissemination (2, 3, 7) . Given the integrin repertoire expressed on the cell aggregates recovered from the patient ascites fluid, it is demonstrated that the cells then adhere to surfaces and implant within the peritoneum via the binding to the monolayer of mesothelial cells and to the extracellular matrix such as fibronectin and type I collagen (2, 3, 7) .
Twenty years ago, peritoneal carcinomatosis was seen as an incurable pathology requiring palliative care only. However, the introduction of loco-regional therapies combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) based on platinum salts or taxanes changed the management of this disease (9) (10) (11) . Signal targeted therapies, such as those targeting PI3K (phosphoinositide 3-kinase) /Akt pathway, are currently tested in these patients with hopes of improvement of disease-free survival rates (12) (13) (14) .
Tumour cell resistance to chemotherapy is now largely considered as enhanced in multicellular 3-dimensional (3D) structures. As an example, EMT-6 mammary tumour cells are more resistant to alkylating agents (Cyclophosphamide, Cisplatin, Thiotepa) when grown in 3D spheroids (2, 15) . Single or clustered cells can detach from breast or prostate primary tumours and can then be found in the bloodstream (16) . Clusters of cells have an increased ability, as compared to single cells, to maintain cohesion and to survive once detached from breast primary tumours.
Studying the formation of these aggregates and their resistance to treatment is also of major interest to improve understanding and therapeutic care of ovarian peritoneal carcinomatosis by targeting transcoelomic migration (16) . In the peritoneal cavity, the formation and properties of these peritoneal tumoural aggregates are still poorly understood.
It is also largely accepted that microenvironment contributes to resistance to chemotherapy (17) . Tumour stromal cells provide an environment promoting metastatic disease and resistance to treatments. Among microenvironment cells, mesenchymal stem cells (MSC) can be mobilized from bone marrow as well as from neighbouring organs at inflammation site resulting from tumour development, including in peritoneum (18, 19) . MSCs are a potential source of various cell types including tumour-associated fibroblasts (TAFs). MSC and TAFs have been shown to contribute to tumour cells' ability to form spheroids called tumourospheres under anchorage-independent culture conditions, increasing their capacity to induce tumour formation in vivo after mouse xenografts (20, 21) . The role of MSC in multicellular 3D culture of tumoural cells is poorly known.
The class I PI3K / Akt axis is one of the most commonly deregulated pathway in cancers, particularly in ovarian cancer, and could have a preponderant role in spheroids formation, as suggested by its involvement in regulation of the actin cytoskeleton (22) (23) (24) . There are 4 isoforms of class I PI3K in Vertebrates: α, β, γ and δ. These heterodimeric enzymes are composed with a catalytic subunit called p110 associated with a regulatory subunit. PI3K activation results in the phosphorylation of phosphatidylinositol 4,5 biphosphate (PIP2) into phosphatidylinositol 3,4,5 triphosphate (PIP3) which acts as a second messenger in the cell. Downstream signals of PI3K, including the members of the Akt / mTOR (mammalian target of rapamycin) pathway, are numerous and involved in many cellular processes like cell cycle progression and actin cytoskeleton rearrangement (25) (26) (27) . Activation of the PI3K pathway is associated with increased migration and invasion of different subpopulations of ovarian cancer cells, making this signaling pathway a predictor of invasive and migratory potential of ovarian tumour cells (28) . Amongst the 4 class I PI3K encoding genes, PIK3CA gene encoding PI3Kα was found mutated in 6 to 33% of patients depending on the studies, and amplification or copy gain of this gene are found in 13 to 39.8% of the cases (29, 30) ; these alterations are non-exclusive. Regarding the repartition of these alterations in the different subtypes of ovarian carcinomas, in high grade serous carcinomas, PIK3CA mutations are less frequent while amplifications are commonly found. The genetic landscape of ovarian carcinomas suggests that PI3K inhibitors, and in particular those targeting PI3Kα, could be tested in this pathology. Clinical trials with BYL719 (Alpelisib), a PI3Kα-selective inhibitor, in combination with estrogen receptor inhibitors already show clinical benefits with lower toxicity compared to the use of pan-PI3K inhibitors. BYL719 (Alpelisib) have just been approved for breast cancer (31, 32) , demonstrating the clinical interest of studying PI3K isoform-selective functions.
The importance of PI3Kα activity in tumoural aggregates from ovarian origin is unknown.
This study objective is to validate a model of ovarian cancer cell aggregates and associated ascites, to demonstrate the involvement of PI3Kα during transcoelomic tumourosphere formation and their maintenance. For that purpose, we setup a 3D culture protocol allowing the formation of homotypic or heterotypic (with MSC) tumourospheres similar to tumour aggregates found in ovarian cancer ascites that we treated with PI3Kα-selective inhibitors. The use of these PI3Ktargeting molecules is understudied in peritoneal carcinomatosis. Thus, our demonstration of a PI3Kα-driven formation of multi-cellular aggregates and their relation to mesenchymal stroma offers new therapeutic strategies to patients with peritoneal carcinomatosis.
RESULTS

Peritoneal tumour cells from ascites biopsies form aggregates which growth is delayed with high number of cells
Ascites are biopsied and are analysed to detect the presence of ovarian adenocarcinomatous cells. We first described the tumour cell aggregates found in ascites associated to ovarian adenocarcinomas in patients, which diagnostic was confirmed on cytospin and embedded preparation with routine coloration analysis with PAP, MGG, PAS and EpCAM IHC staining (Fig.   1A ). The majority of the ascites (11/12 patients) were composed of isolated tumoural cells in limited amount with numerous aggregated tumoural cells ( Fig. 1A ). Only one case presented numerous isolated cells in association to aggregates. We observed a heterogeneity between patients in term of repartition of cellular aggregates, with patients with a high number of cell aggregates in ascites showing a better survival compared to patients with low aggregate number ( Fig. 1B , Suppl. Table   1 ). When grown in 3D-favorable conditions, ascites cells formed dense spheroids (Fig. 1C ). In order to better reproduce peritoneal carcinomatosis development of transcoelomic aggregates ( Fig. 1D ), we first developed a 3D culture system of peritoneal tumour cells derived from ovarian cancer SKOV-3 expressing GFP ( Fig. 1E ). After 14 days, we analysed the influence of cell numbers in aggregates and observed an increase of 75% and 13% of tumourosphere area when 5,000 and 10,000 cells were seeded respectively ( Fig. 1F ). Increase in number of initial cells appear to slow tumourosphere growth ( Fig. 1E and F). Interestingly, area evolution (+24% in 7 days) ( Fig. 1F ) was correlated with expression of fluorescent GFP (+ 6% in 7 days) indicative of transcriptional/translational cellular activity ( Fig. 1G, left) , and metabolic activity indicative of cell survival (+ 29% in 7 days) ( Fig. 1G right) . We then carried out 3D cultures with 10,000 MSC and observed totally different aggregates evolution profiles compared to SKOV-3 cells with a very fast cell aggregation the day after seeding, and a more than 60% aggregate area decrease within 14 days compared to initial area (Suppl. Fig. 1A and B ). We also observed fibrous-like structure formations within MSC aggregates whose nature remains to be determined (Suppl. Fig 1C) . We then cocultured 5000 GFP-expressing SKOV-3 cells with different quantities of Qdot-labeled MSCs (5, 50 , 500 or 5000) as a model of stromal cells found in ascites and observed morphology, area and fluorescence localisation of these heterotypic tumourospheres ( Fig. 1H and Suppl. Fig. 1D , E, F) (38) . Heterotypic tumourosphere area decreased proportionally to the number of MSC with an apparent increased cohesion ( Fig. 1H ). On the other hand, GFP fluorescence corresponding to tumour cells did not vary regardless of MSC number, indicating that these cells induced a compaction of the tumourospheres without modifying tumour cell proliferation (Suppl. Fig. 1D and E). At a high ratio and 7 days after seeding, MSC cells clustered in the center of tumourospheres and colocalized with tumour cells (yellow staining, Suppl Fig. 1F ).
Small sized tumourospheres show cellular growth and the addition of MSC to tumour cell spheroids results in increased compaction of the tumourospheres, reminiscent to what we observe with the formation of tumourospheres from patients' ascites cells.
PI3Kα inhibition prevents ovarian cancer cell tumourosphere formation.
The PI3K/Akt pathway plays a role in cell proliferation and survival but is also described as involved in the regulation of the actin cytoskeleton suggesting a role in tumourosphere formation (22, (25) (26) (27) . In order to determine the action of this pathway in the formation of SKOV-3 GFP multicellular aggregates, we treated them at seeding and 3 days later with PI3Kα-selective inhibitors A66 and BYL719 ( Fig. 2A ). We confirmed a concentration-dependent inhibition of Akt phosphorylation inhibition on S473 and T308 upon treatment with A66 and BYL719 ( Fig. 2B-D) , indicating 1-that PI3K pathway is constitutively activated in SKOV-3 cells, 2-that this activation is highly dependent on the PI3Kα isoform and 3-that the pharmacological agents used prevent its activity.
We next compared the efficiency of a low (1µM) and medium (10µM) dose of PI3K inhibitors; in clinical trials, measured concentration of BYL719 in plasma are of the order of 50µM (39) . After 4 and 7 days of treatment with 10 µM of BYL719, we observed a complete reduction of the tumourosphere area and a total loss of their fluorescence ( Fig. 2E -G). Aggregates treated with 10 µM of A66 or 1 µM of BYL719 had comparable evolution profiles ( Fig. 2E ) with a decrease in tumourosphere area of about 30% compared to the control at d4 (Fig. 2F ). We compared our results to the reference treatment of ovarian cancer, cisplatin, at doses found in patients (0.5µM and 5µM), 5µM being a dose close to toxicity in patients (40) . A total disruption of SKOV-3 tumourospheres was observed only at high concentrations and after 7 days of treatment ( Fig. 2H -J). Hence, we observed a significant alteration of tumourosphere cohesion, tumourosphere area ( Fig These results suggest that PI3Kα inhibitors are able to reduce tumourosphere formation, while having a cytotoxic effect in a dose-dependent manner on these aggregated or non-aggregated cells whereas cisplatin appears to present only cytotoxic effect at high concentration close to patient toxicity dose and in a delayed manner.
PI3Kα selective inhibition prevents ovarian cancer cell tumourosphere maintenance.
In order to measure PI3Kα inhibitor effects on tumourosphere maintenance, we treated already established SKOV-3 GFP cell aggregates with PI3Kα inhibitors (A66 and BYL719) or cisplatin one day after tumourosphere formation and 3 days later (Fig. 3A) . In order to test PI3Kα specificity of action amongst all PI3K isoforms on this mechanism, we also treated these tumourospheres with PI3Kβ (TGX-221) and PI3Kβ/δ inhibitors (AZD8186). Unlike cisplatin, PI3Kα inhibitors retained a concentration-dependent effect (although not significant) at d4 (Suppl. Fig. 2A and B) . The cytotoxic effect of cisplatin observed in 2D was therefore abolished by 3D culture, whereas, albeit diminished, PI3Kα inhibitor treatment still showed cytotoxic effects in tumourospheres ( Fig. 4B -E).
In order to further analyse organization and distribution of living and dead cells within tumourospheres under treatment, we labeled living cells in green (calcein) and dead cells in red (EthD-1). First, we found that when we analyse living cells, displayed in white, with their area quantified ( Fig. 4 F-H), BYL-719 significantly decreased this marker of living cell ( Fig. 4 . G, H).
SKOV-3 cell treatment with PI3Kα inhibitors caused an alteration in the tumourosphere cohesion
and tended to increase dead cell amount (Suppl. Fig. 2C ). Only 10 μM of BYL719 caused a significant decrease in living cell area ( Fig. 4F and G) . As observed previously, a 0.5 μM cisplatin concentration did not modify aggregates morphology. Tumourospheres disintegration and living cell surface decrease was only detected after 7 days with 5 μM of platinum salt treatment ( Fig. 4F and H). As observed before, PI3Kα inhibitors induced a rapid decrease of tumourosphere cohesion and viability ( Fig. 4F and G, Suppl. Fig. 2 ) compared to cisplatin which was followed by a tumourosphere disintegration only at high concentration after 7 days of treatment ( Fig. 4F and H) .
Regarding the localization of living and dead cells, untreated SKOV-3 tumourospheres appeared to have a dead cell inner core, while treatment with PI3Kα inhibitors suppressed this core, with a staining spread on the whole area of the tumourosphere, in particular in the outer layer of the tumourosphere (Suppl. Fig. 2C ). As observed before, the PI3Kβ specific inhibitor TGX-221 at 1µM did not alter SKOV-3 WT tumourospheres morphology ( Fig. 4F ) and area ( Fig. 4G) . At high concentration, concentration at which the selectivity towards PI3Kβ and class PI3Ks is not demonstrated, we observed an unexplained increased area of living cells despite a loss of cohesion ( Fig. 4F) , combined with decreased number of inner dead cells in comparison to other PI3Kβtargeting inhibitors at similar drug concentration (Suppl. Fig. 2C ). AZD8186 only slightly modified living cells area ( Fig. 4G ) but seemed to alter the tumourosphere morphology by altering their cohesion at both concentrations ( Fig. 4F ).
Despite a decreased effect in 3D culture, PI3Kα inhibitor is shown as the most effective treatment as compared to the conventional treatment.
PI3K inhibitors decrease tumourosphere survival in presence of cisplatin.
If used in the clinic for the treatment of ovarian cancer, inhibitors of PI3K will be tested in combination (39) . SKOV-3 cells were cultured in 3D similarly to previous experiments and treated with a combination of treatments associating a fixed 1 µM concentration of PI3K inhibitors with increased concentrations of cisplatin. The tumourosphere area, the metabolic activity and the surface of living cells were quantified ( Fig. 5 ).
Combination of low concentration of cisplatin with PI3Kα inhibitors appeared to alter more efficiently SKOV-3 GFP tumourospheres morphology compared to control (cisplatin alone) but not significantly more than the corresponding inhibitor alone ( Fig. 5A et B) . These results were confirmed by measurements of tumourosphere area ( Fig. 5C ) and of the area of calcein positive alive cells ( Fig. 5E ). However, albeit non-significant, the metabolic activity tended to decrease only with the combination of therapeutic agents (Cisplatin with A66, BYL-719, TGX-221, AZD8186), in particular with α-selective inhibitors (Fig. 5D ). Moreover, a greater effect of the combination cisplatin low dose and PI3Kα inhibitors on decreasing the area of metabolically active cells seemed to be observed compared with the condition cisplatin 5 µM ( Fig. 5E ). Results obtained with combination of cisplatin with TGX-221 and AZD8186 were not significantly changed neither for area nor for living cell numbers in the SKOV-3 GFP tumourospheres as compared to cisplatin alone.
Differences in the effects observed with the three different assays show that the key combined action of PI3Kα inactivation and cisplatin treatment consists in decreasing cell survival upon tumourosphere dissociation.
Finally, addition of MSC which compacted the tumourosphere tended to decrease the efficiency of PI3Kα inhibitors on tumourosphere area but they always seemed to have an effect ( Fig. 6A and B ). The absence of direct effect of all PI3K inhibitors on MSC was verified (Suppl. Fig. 3 ).
In conclusion, the combination therapy of PI3Kα with cisplatin leads to tumourosphere survival decrease possibly via a dissociation of the tumour cell aggregate.
DISCUSSION
Because of a frequent late diagnosis, ovarian cancers associated with peritoneal carcinomatosis most often develop ascites. This metastatic process involves a transcoelomic migration step requiring tumour cell aggregation within the peritoneal cavity. This threedimensional structure allows tumour cells to better survive to conventional chemotherapies (2, 41) .
The current therapeutic arsenal lacks treatments targeting the metastatic disease, which represents a major public health issue due to its morbidity and mortality. To date, HIPEC has therapeutic interest in peritoneal carcinomatosis treatment but remains poorly practiced because of the potential toxicities (42) (43) (44) (45) (46) . Our data demonstrate that PI3Kα should be added to their therapeutic arsenal.
We found tumor aggregates in all the ovarian cancer patients' ascites we studied.
Surprisingly, patients with a high number of cell aggregates showed a better survival than patients with low aggregate number ( Fig. 1A-C) . These clinical observations reinforce the need to better understand ovarian tumor cell aggregate formation.
In this study, we developed a 3D culture method to better mimic the aggregate formation observed within the ascites fluid and responsible for short term peritoneal carcinomatosis. We used ovarian tumour cells SKOV-3 coming from ascites and realized tumourospheres in round-bottomed plates treated to prevent cell adhesion (47) . After only a few hours, ovarian tumour cells form round or elliptical structures typically corresponding to those described in the literature (48) , reproduced as well with 3D culture of patients (Fig. 1C ). SKOV-3 tumourospheres area increases over time and most of the cells composing the core of the tumourosphere are dead (Suppl. Fig. 2C ) similar to observations of other teams (49, 50) . However, cell density and GFP fluorescence do not significantly vary over time indicating a stability in the cell number composing the tumourospheres (Fig. 1E, G) . PI3K, and more particularly the α isoform, play a role in the rearrangement of the actin cytoskeleton (22, 51) . Actin involvement in migration and invasion is no longer to be proven and, according to our hypothesis, PI3Kα would facilitate ovarian tumour cell aggregate formation (25) (26) (27) . In order to validate this hypothesis, we treated SKOV-3 cells tumourospheres during seeding with different concentrations of PI3Kα inhibitors, A66 (33) and BYL719 (34) . After treatment of these aggregates, and regardless of concentration used, we observe in microscopy sphere disorganization up to complete disintegration for 10µM of BYL719 treatment. Assessment of cytotoxicity was carried out in parallel on these tumourospheres. As an example, BYL719 at 1 μM concentration decreases aggregate area of 29.1% but only decreases of 8.9% in living cells percentage after 7 days. The fact that the treatment is carried out at the seeding time and that the morphology modifications are observed in a short time show that this disorganization is not only a result of an inhibitor cytotoxicity with regard to percentages of remaining viable cells obtained.
Because most of the patients with ovarian cancer already present ascites fluid containing cell aggregates at the initiation of the treatment (52), we sought to determine the role of PI3K on the maintenance of existing tumour aggregates. We treated our tumourospheres the day after seeding. While a treatment with 10 μM of BYL719 during cell seeding causes a total reduction in measurable sphere area after 7 days, the same treatment started one day later results in a 68.5% reduction in sphere area. This efficacy reduction observed after PI3Kα inhibitor treatment could be due to a lack of treatment penetration within the spheres (53) . PI3Kα seems to have a role in both formation and maintenance of ovarian tumour cell aggregates.
Here, SKOV-3 cells cultured in 3D show a 33.4% increase in resistance to 10 µM of BYL719 treatment compared to a 2D culture. Resistance to cisplatin, a standard treatment in HIPEC for ovarian cancer, is increased by approximately 70% by this 3D culture ( Fig. 4) . It has been repeatedly demonstrated that 2D cytotoxicity studies do not account for complete tissue physiology and overestimate the cytotoxic potential of the tested molecules (15, 54) . Aggregate formation study has led to the discovery of multicellular resistance existence and has demonstrated protection of ovarian carcinoma cells against apoptosis induced by cisplatin. In a 3D culture, these cells are 18, 15 or 58 times more resistant to cisplatin at 25, 50 and 100 μM respectively (15) . In addition, proliferation within the spheres decreases in comparison with cells cultured in 2D, partially explaining these cells escape to such treatments induced death targeting cells in replication (15, 55) .
The comparison of our 2D and 3D cytotoxicity results accounts for the same type of resistance for SKOV-3 GFP cells to that observed in the literature. Inhibitors seem to maintain a concentrationdependent effect at day 4 compared to cisplatin, which at this stage is ineffective (Suppl. Fig. 2A and B), suggesting that inhibitors retain an earlier action on tumourosphere cohesion, compared with cisplatin.
Whatever the timing of treatment, cisplatin has a significant effect only at a high concentration of 5 μM ( Fig. 2I and 3H ). As for PI3K inhibitors, cisplatin has a lesser efficacy when used the day after seeding compared to a treatment during cell seeding. In addition, in 3D, PI3Kα inhibitors induce a quicker effect than cisplatin. BYL719 leads to a significant reduction of the area parameter at low concentration of 0.1 μM (Fig. 3D ) which allows us to consider an effect on peritoneal carcinomatosis while maintaining a low toxicity.
We also conducted these experiments with PI3Kβ inhibitors, TGX-221 (35) and AZD8186 (36) . TGX-221 has no significant effect on either sphere area or metabolism ( Fig. 3E and 4D ). On the other hand, AZD8186 induces a significant decrease of tumourosphere area at high concentration which could be due to its action of PI3Kα. Indeed, PI3Kα IC50 of A66 are similar (32 and 35 nM respectively) ( Fig. 3E and 4D) (36) . Overall, we show that the maximum effects on tumourosphere area are obtained with PI3Kα inhibitors, showing a specificity of action of this isoform.
Our hypothesis that PI3Kα acts on spheroid development seems to be verified by the experiments carried out in this study. PI3Kα action on actin cytoskeleton could be the source of this effect on spheroids (27, 56) . This hypothesis is reinforced by the knowledge of existing link between the polymerized actin and the adhesive molecules such as E or P cadherins. P-cadherin expression promotes migratory potential and aggregation of circulating ovarian cancer cells into multicellular aggregates (57) . These elements highlighting actin role could in part explain PI3Kα involvement in cell clustering (58, 59) .
Intercellular interactions between two same cell types have a role in metastatic disease development. By serial intraperitoneal injection of green and red fluorescent cells, newly introduced cancer cells have been shown to adhere preferentially to existing tumours (60) . Therapies targeting adhesion between cancer cells of the same type, such as PI3Kα inhibitors, are worthy of consideration for improving peritoneal carcinomatosis management. Tumour aggregate disorganization induced by PI3Kα inhibitors would allow a better cisplatin bioavailability within the tumourospheres by breaking decreasing gradient of diffusion from the periphery to the center of these 3D structures (61) . Another hypothesis for increased efficiency of cisplatin upon PI3Kα inactivation could be that tumourosphere dissociation decreases the solid stress that build up in the 3D culture (62) and with increase liquid pressure (63) or the shear stress caused by ascites fluid motion in the peritoneal cavity (8) , or the tensile stress caused by MSC, releasing the proliferation rate and allow cisplatin to function. This remains to be demonstrated in follow-up studies.
One parameter that we find key to patient prognosis is the tumour aggregate size. This could account for the heterogeneity of treatment response of patients with chemotherapeutic agents.
Others also found that forming spheroids of small size is more relevant to patient disease (64). If compression, interstitial pressure, tension increase invasion features through epithelial-tomesenchymal transdifferentiation (EMT) (62, 63) , our clinical data demonstrate that less aggressive cells tend to grow in larger multicellular aggregates which could decrease their proliferation rate and increase their death ratio. Finding molecular determinant of such behavior could be of interest to understand the progression of ovarian cancer. Indeed, others found that morphology of human donor ascites aggregates is conserved in tumour-bearing mice injected by i.p. with these cells (38) .
In conclusion, our results show that isolated cells obtained from small tumour aggregates can be treated with PI3Kα inhibitors. This is all the more important given that we find that patients with smaller aggregates presented a poorer prognosis. These dissociated cells are shown to be more sensitive to conventional therapies (15, 54) and PI3K-driven tumour cell aggregate dissociation demonstrates the potential interest of PI3Kα inhibitors in combination therapy with this type of chemotherapy. Hence, our results that demonstrate the crucial role of PI3Kα in the formation and maintenance of ovarian tumour cells aggregates, make this enzyme a therapeutic target of interest for peritoneal carcinomatosis treatment (Fig. 7) . Indeed, the use of an intraperitoneal PI3Kα inhibitor pretreatment separating aggregates into individual cells will allow the sensitization of tumourospheres to the treatments used in HIPEC and constitutes a promising alternative to improve management of a pathology with a very poor prognosis. 1A ). Microscopic examination of the colored slides allows to establish a formula indicating the percentage of the different mononucleated cells and the detection of carcinomatous cell. The number of aggregates on the cytospin spot and the number of cells in the aggregates is noted as well as the aggregate density (Fig. 1A, top) . A normalized aggregate number has been determined by multiplying these two parameters. Rich aggregates ascites have a normalized aggregates number above 100,000 while poor aggregates ascites have a normalized aggregates number below 100,000.
MATERIAL AND METHODS
Patient ascites-derived cell tumourospheres
To assure malignancy, immunocytochemistry is performed with EpCam (clone Ber-EP4 IVD 05435676001 Ventana Roche). The cytospin cell preparation is fixed 10 min in preservCyt solution (Cytyc Corporation, Marlborough, Mass) at room temperature and processed in an automated staining plateform (Ventana bench mark Ultra). After primary antibody incubation, the detection used is Ultra view Dab (VENTANA roche) (Fig. 1A, bottom The culture medium is supplemented with 10% FCS (fetal calf serum), 1% L-glutamine, 1%
penicillin-streptomycin and 0.01% plasmocin (Invitrogen). 
Cell lines and culture conditions
Living cell assay assessed by mitochondrial reductase activity assay in 2D (MTT)
One thousand patient-derived tumoural cells or SKOV-3-GFP and SKOV-3-WT cells, with or without increasing amount of MSC cells are seeded in 96-well plates. The following day, cells are treated with specific inhibitors of PI3Kα, A66, BYL719 at increasing concentrations of 0.01 to average of the corresponding experiment (representing 100% of the surface). In parallel, at the end of d0, d3 and d6 treatment, the living cells are quantified by colorimetric assay using the Alamar Blue™ cell viability reagent (Invitrogen). Average absorbance is reported to the control on the day of measurement (representing 100% of living cells). To set up the conditions, we seeded 5,000 or 10,000 SKOV-3 GFP cells in round-bottom plates treated to enhance cell aggregation and measured by microscopy the evolution of area of tumourospheres thus formed. Of note, addition of methylcellulose (MC) (cellulose polysaccharide derivative promoting cell suspension by making medium more dense and viscous) in the culture medium did not improve tumourosphere formation (not shown), as opposed to data described in (37) . MC seems to delay, by about 4 days, the aggregation of SKOV-3 GFP cells (not shown). Plate centrifugation (one minute at 300g) did not bring any modification to tumour aggregates formation either (not shown).
Qdot® Cell labelling of MSC cells
The labelling is performed according to the supplier's recommendations; in details, the equimolar mix of the labelling kit at dilution 1/100 is incubated for 1 hour at room temperature and is then applied directly to the cell cultures. This is followed by a 45 min incubation at 37° C, 5% CO2 under a humid atmosphere. Labeled cells are then washed twice with complete growth medium.
Assessment of cell viability with LIVE/DEAD® cytotoxicity assay in 3D
SKOV-3 WT cell tumourospheres are cultured and treated as described previously. On d1, d3 and d7, live (in green) and dead (in red) cells are labeled using the LIVE/DEAD® kit 
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RESULTS
We focused on ovarian cancer clinical situation, where more than a third of patients present tumour cells in their peritoneal cavity, in a liquid that is called ascites. We found that the size of the tumour aggregates influenced positively the prognosis of the patients and that dissociation of the tumour aggregates led to an increased sensitivity to therapies. The protumourigenic signalling driven by PI3Kα, one of the gene the most mutated in cancers, by promoting compaction of small sized tumour aggregates favoured therapy resistance. The clinically approved therapies that target PI3Kα decreased the survival of ovarian cancer cells from ascites.
CLINICAL IMPACT
We hence identified a signaling pathway of interest for the treatment of advanced ovarian cancer, which could limit the progression of this poor prognosis cancer by ascites cancer cell dissemination. . A normalized aggregates number has been determined by multiplying these two parameters. Rich aggregates ascites have a normalized aggregates number above 100,000 while poor aggregates ascites have a normalized aggregates number below 100,000.
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